About Us
Company History
The Team
Executive Management
Board of Directors
Scientific Advisory Board
Partners
|
Product
|
Science
Scientific Overview
Epitope-based Approach
Scientific Publications
|
Influenza
The Flu Virus
The Flu and Global Health
Useful Links
|
News & Media
Press Releases
Events & Presentations
BiondVax in the News
Press Kit
|
Investor Relations
Stock Information
Ownership Structure
Financial Reports
Regulatory Filings
Analysts
|
Careers
|
Contact Us
Home
>>
News & Media
>> Press Releases
Press Releases
News & Media
►
Press Releases and
Company News
Events and
Presentations
BiondVax in the News
Press Kit
Press Releases & Company News
2011
29 August 2011
BiondVax Announces Receipt of IRB Ethics Committee Approvals for Initiation of Second Phase II Clinical Trial for Universal Flu Vaccine
16 June 2011
BiondVax Announces Positive Phase IIa Results for Universal Flu Vaccine
31 May 2011
BiondVax to Present Phase IIa Results at 2011 BIO International Convention
2010
9 November 2010
BiondVax Raises $1.25 million Using Yorkville SEDA
11 October 2010
BiondVax Begins Phase IIa Study for Universal Flu Vaccine
28 September 2010
BiondVax to Present at World Vaccine Congress 2010 in Lyon, France
17 August 2010
BiondVax Announces Receipt of Ethics ('Helsinki') Committee Approvals for the Initiation of first Phase II Clinical Trial for Universal Influenza Vaccine
28 July 2010
Frost & Sullivan Awards '2010 European Influenza Vaccines Technology Innovation Award' to BiondVax Pharmaceuticals for Universal Influenza Vaccine
